Početna stranicaSGEN • BMV
add
Seagen
Preth. zaklj. cijena
3.711,48 $
Godišnji raspon
3.711,48 $ - 3.711,48 $
Tržišna kapitalizacija
43,15 mlr. USD
P/E omjer
-
Prinos dividende
-
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
(USD) | ruj 2023.info | Godišnja promjena |
---|---|---|
Prihod | 648,65 mil. | 27,11 % |
Operativni troškovi | 262,69 mil. | 24,86 % |
Neto dohodak | −215,79 mil. | −13,09 % |
Neto profitabilnost | −33,27 | 11,02 % |
Zarada po dionici | −1,15 | −11,65 % |
EBITDA | −209,33 mil. | −19,47 % |
Efektivna porezna stopa | 0,26 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
(USD) | ruj 2023.info | Godišnja promjena |
---|---|---|
Gotovinska i kratkoročna ulaganja | 1,24 mlr. | −29,86 % |
Ukupna imovina | 3,63 mlr. | 0,42 % |
Ukupne obveze | 1,08 mlr. | 35,94 % |
Ukupni kapital | 2,55 mlr. | — |
Dionice u optjecaju | 188,66 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 274,52 | — |
Povrat imovine | −16,01 % | — |
Povrat kapitala | −21,12 % | — |
Tok novca
Neto promjena novca
(USD) | ruj 2023.info | Godišnja promjena |
---|---|---|
Neto dohodak | −215,79 mil. | −13,09 % |
Gotovina od poslovanja | −35,82 mil. | 58,21 % |
Gotovina iz ulaganja | 142,49 mil. | 119,31 % |
Gotovina iz financiranja | 15,52 mil. | −15,59 % |
Neto promjena novca | 119,90 mil. | 1.958,05 % |
Slobodan tok novca | 71,52 mil. | 1.141,10 % |
Više
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The company's flagship product Adcetris is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program
to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Wikipedia
Glavni izvršni direktor
Osnovano
15. srp 1997.
Web-lokacija
Zaposlenici
3.256